<DOC>
	<DOC>NCT00032747</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, parallel-group forced up-titration study. Randomization will be stratified according to the patient's baseline serum sodium concentration (137-144 and &lt;137 mmol/L). The dose of study drug will be increased to the next level on Day 15, and the total duration of the double-blind treatment period is 120 days.</brief_summary>
	<brief_title>Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Vasopressins</mesh_term>
	<mesh_term>Arginine Vasopressin</mesh_term>
	<criteria>Men or women with chronic heart failure (NYHA Class IIIB and IV). Women must be postmenopausal or surgically sterilized; they cannot be pregnant or nursing. Age 21 to 80 years. Chronic heart failure of at least 3 months duration. For 2 months prior to screening, patients must have had symptoms at rest or on minimal exertion for more than 50% of the time. For 2 weeks prior to screening, patients must have had symptoms at rest or on minimal exertion for more than 90% of the time. Patients must be receiving a diuretic and an ACE inhibitor (or an angiotensin II receptor antagonist) for the treatment of heart failure. Patients may be receiving digoxin, a betablocker or spironolactone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>Heart Disease</keyword>
</DOC>